| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b53290ef881bc16e92cfbaf0cd9605a7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2025-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2002-91533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0068 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-915
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M29-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M31-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-007 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M25-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M29-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M25-00 |
| filingDate |
2004-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53f322d4662950d1d7cc0510e17cb440
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f5e0adc4b8e1f6b28d744a4364d599f3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d64fd04a5cdcc9c66410d32896af5faf |
| publicationDate |
2005-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1608426-A1 |
| titleOfInvention |
Implantable medical device and method for in situ selective modulation of agent delivery |
| abstract |
The present invention provides an implantable medical device (10), systems employing the device, and methods of using the device. The implantable medical device includes a device body containing a beneficial agent arranged for delivery from the device body to an implantation site within a patient. The beneficial agent is configured to be selectively modulated after implantation within the patient by an activating/deactivating means (200). Furthermore, the beneficial agent at a first region of the device body can be modulated by the activating/ deactivating means to create a different agent delivery profile than the beneficial agent at a second region of the device body. |
| priorityDate |
2003-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |